Cliff Asness's CYTK Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 236,925 shares of Cytokinetics, Incorporated (CYTK) worth $14.77 M, representing 0.01% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in CYTK, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 327,745 shares. Largest reduction occurred in Q4 2025, reducing 276,365 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -276,365 | Reduce 53.84% | 236,925 | $62.36 |
| Q3 2025 | +165,551 | Add 47.61% | 513,290 | $54.96 |
| Q2 2025 | +327,745 | Add 1639.22% | 347,739 | $33.04 |
| Q1 2025 | -13,259 | Reduce 39.87% | 19,994 | $40.19 |
| Q4 2024 | -4,104 | Reduce 10.99% | 33,253 | $47.04 |
| Q3 2024 | +3,956 | Add 11.84% | 37,357 | $52.80 |
| Q2 2024 | +3,168 | Add 10.48% | 33,401 | $54.18 |
| Q1 2024 | +2,523 | Add 9.11% | 30,233 | $70.11 |
| Q4 2023 | -1,669 | Reduce 5.68% | 27,710 | $83.49 |
| Q3 2023 | -4,892 | Reduce 14.27% | 29,379 | $29.46 |
| Q2 2023 | -5,431 | Reduce 13.68% | 34,271 | $32.62 |
| Q1 2023 | -1,922 | Reduce 4.62% | 39,702 | $35.19 |
| Q4 2022 | +812 | Add 1.99% | 41,624 | $45.82 |
| Q3 2022 | +2,637 | Add 6.91% | 40,812 | $48.44 |
| Q2 2022 | +1,267 | Add 3.43% | 38,175 | $39.29 |
| Q1 2022 | +543 | Add 1.49% | 36,908 | $36.82 |
| Q4 2021 | +26,230 | Add 258.81% | 36,365 | $45.59 |
| Q2 2021 | -5,642 | Reduce 35.76% | 10,135 | $19.83 |
| Q1 2021 | -604 | Reduce 3.69% | 15,777 | $23.26 |
| Q4 2020 | -3,396 | Reduce 17.17% | 16,381 | $20.76 |
| Q3 2020 | -1,113 | Reduce 5.33% | 19,777 | $21.64 |
| Q2 2020 | -769 | Reduce 3.55% | 20,890 | $23.55 |
| Q1 2020 | +1,443 | Add 7.14% | 21,659 | $11.77 |
| Q4 2019 | +4,379 | Add 27.65% | 20,216 | $10.59 |
| Q3 2019 | +15,837 | New Buy | 15,837 | $11.37 |
| Q3 2018 | -15,186 | Sold Out | 0 | $0.00 |
| Q1 2018 | -11,723 | Reduce 43.57% | 15,186 | $7.18 |
| Q4 2017 | +1,310 | Add 5.12% | 26,909 | $8.14 |
| Q3 2017 | -4,963 | Reduce 16.24% | 25,599 | $14.49 |
| Q2 2017 | +5,937 | Add 24.11% | 30,562 | $12.11 |
| Q1 2017 | +5,203 | Add 26.79% | 24,625 | $12.83 |
| Q4 2016 | -5,369 | Reduce 21.66% | 19,422 | $12.15 |
| Q3 2016 | +6,311 | Add 34.15% | 24,791 | $9.20 |
| Q3 2015 | +18,480 | New Buy | 18,480 | $6.71 |
| Q3 2014 | -18,293 | Sold Out | 0 | $0.00 |
| Q2 2014 | -9,700 | Reduce 34.65% | 18,293 | $4.76 |
| Q1 2014 | +1,200 | Add 4.48% | 27,993 | $9.50 |
| Q3 2013 | +26,793 | New Buy | 26,793 | $7.58 |
Cliff Asness's Cytokinetics Incorporated Investment FAQs
Cliff Asness first purchased Cytokinetics, Incorporated (CYTK) in Q3 2013, acquiring 26,793 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Cytokinetics, Incorporated (CYTK) for 44 quarters since Q3 2013.
Cliff Asness's largest addition to Cytokinetics, Incorporated (CYTK) was in Q2 2025, adding 347,739 shares worth $11.49 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 236,925 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $14.77 M.
As of the Q4 2025 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Cytokinetics, Incorporated (CYTK) was 513,290 shares, as reported at the end of Q3 2025.